



“Achieving the elimination of viral hepatitis within evolving health systems”

TUESDAY 7 JUNE, 2022

Time	Outline
12.00-13.15	<p>Welcome and High-Level Panel</p> <p>Welcome and moderator: Dr Su Wang, Chairperson, World Hepatitis Summit 2022 Programme Committee, Past President, World Hepatitis Alliance Medical Director, Viral Hepatitis Programs and Center for Asian Health Cooperman Barnabas Medical Center, RWJBarnabas-Rutgers Medical Group, USA</p> <p>Speakers: Helen Clark, Former Prime Minister, New Zealand (TBC) Dr Tedros Adhanom Ghebreyesus, Director-General, World Health Organization Jeannette Kagame, First Lady of Rwanda (TBC) Dr Seth Berkley, Chief Executive Officer, GAVI (TBC) Dr Philippe Duneton, Executive Director, Unitaid (TBC) Charles Gore, Executive Director, Medicines Patent Pool Amitabh Bachchan, Bollywood veteran and WHO Goodwill Ambassador for Hepatitis in the South-East Asia Region</p>
13.15-15.15	<p>New momentum and high impact through the new WHO Global Health Sector Strategy</p> <p>➤ This session will focus on presenting the progress in viral hepatitis elimination and the new WHO Global Health Sector Strategy. Presentations around the different Strategic Directions will illustrate country progress, innovations, community voices and what it will take to reach elimination</p> <p>Chairs:</p> <ul style="list-style-type: none"> • Dr Ren Minghui, WHO, Switzerland

- Dr Meg Doherty, WHO, Switzerland

Introduction by chairs

Introducing the new global health sector strategy (2022-2030) and the implication for countries

Dr Meg Doherty, WHO, Switzerland

Panel discussion : Championing global strategy in our different context

Facilitators

Dr Meg Doherty, WHO Switzerland

Andy Seale, WHO Switzerland

Making giant progress towards global elimination- *Dr Mohammed Hassany, Ministry of Health, Egypt*

Leveraging the systems-approach in optimizing UHC for viral hepatitis elimination in India - *Dr Sandhya, Ministry of Health, India*

Promoting universal health care through hepatitis EMTCT in China - *Ministry of Health, China*

Innovations that are needed to reach hepatitis elimination - *Dr John Ward, Coalition for Global Hepatitis Elimination, USA*

Viral hepatitis and global community and PLW Hepatitis - *Rachel Halford, Hepatitis C Trust, UK*

Hepatitis elimination validation pilot report. Lessons learned from pilots in 7 countries (Introducing elimination pilot report)

Dr Olufunmilayo Lesi, WHO, Switzerland

Roundtable discussion and implication for countries

Facilitators:

Dr Olufunmilayo Lesi, WHO, Switzerland

	<p>Niklas Luhmann, WHO, Switzerland</p> <p>Hearing from pilot countries : Georgia, Rwanda, Brazil, Mongolia, Thailand, England</p> <p>Upcoming HCV guidance review <i>Dr Philippa Easterbrook, WHO, Switzerland</i></p> <p>Closing remarks Dr Ren Minghui, WHO, Switzerland</p>
15.30-16.30	<p>Lightning talks: oral abstracts of distinction - Advocacy, awareness and education efforts</p> <p>Chair: TBC</p>
15.30-15.35	<p>Welcome</p>
15.35-15.40	<p>A global open call for enhancing viral hepatitis public engagement and advocacy <i>Dr Tiange Philip Zhang, Loyola University Medical Center, USA</i></p>
15.45-15.50	<p>Have a heart, save my liver! Which countries restrict treatment? <i>Joelle Dountio Ofimboudem, TAG, USA</i></p>
15.55-16.00	<p>The activities to raise awareness of hepatitis patients in term of labor law and health law <i>Dr Hilal - Unalmis Duda, Turkish Liver Foundation, Turkey (TBC)</i></p>
16.00-16.05	<p>Advocacy is a powerful tool to ensure hepatitis C healthcare for PWUD. The Moroccan experience <i>Dr Taha Brahni, Association De Lutte Contre Le Sida (ALCS), Morocco</i></p>
16.05-16.10	<p>Nurses as viral hepatitis advocates: Empowerment through education <i>Dr Aayushi Rastogi, India</i></p>
16.10-16.30	<p>Discussion and Q&A</p>

	<p>Hepatitis-free generation: Preventing mother to child transmission</p> <ul style="list-style-type: none"> ➤ Describing the global burden of mother to child transmission of hepatitis B and gaps in antenatal screening, treatment and infant vaccination ➤ Addressing birth dose coverage globally and implementation challenges to birth dose in different settings ➤ Recognizing the experience of mothers living with viral hepatitis and challenges they face in accessing services for themselves and for their infants <p>Chairs:</p> <ul style="list-style-type: none"> • Lien Tran, The Peter Doherty Institute for Infection and Immunity, WHA WPRO Board Member • Dr Morkor Newman, WHO, Switzerland
16.30-16.37	<p>Welcome and introduction to GVAC</p>
16.37-16.44	<p>The urgency and necessity of preventing mother to child transmission in achieving hepatitis elimination <i>Dr Olufunmilayo Lesi, WHO, Switzerland</i></p>
16.44-16.51	<p>MSF's PMTCT work In Mozambique <i>Kwalila Roberto Tibana, Médecins Sans Frontières (TBC)</i></p>
16.51-16.58	<p>CDA analysis of birth dose coverage in Gavi vs non Gavi countries <i>Devin Razavi-Shearer, Center for Disease Analysis Foundation, USA</i></p>
16.58-17.03	<p>Birth dose vaccine coverage and barriers to timely uptake in Nasarawa And Kano States, Nigeria <i>Chukwuemeka Agwuocha, CHAI, Nigeria</i></p>
17.03-17.08	<p>How mothers with chronic hepatitis B understand and experience PMTCT interventions in Victoria, Australia <i>Nafisa Yussf, The Doherty Institute, Australia</i></p>
17.08-17.13	<p>Familial clustering of hepatitis C virus in Pakistani population <i>Professor Yasir Waheed, Foundation University Islamabad, Pakistan</i></p>

<p>17.13-17.18</p> <p>17.18-17.30</p>	<p>Prevention of mother to child transmission and hepatitis B vaccination of children in Bangladesh (includes Rohingya refugees) <i>Professor Mohammad Ali, National Liver Foundation of Bangladesh, Bangladesh</i></p> <p>Q&A and closing remarks</p>
<p>16.30-16.40</p> <p>16.40-16.45</p> <p>16.45-16.52</p> <p>16.52-16.59</p> <p>16.59-17.06</p> <p>17.06-17.13</p>	<p>From policy to people: Bringing services closer to communities</p> <ul style="list-style-type: none"> ➤ Examining collaborations across sectors which effectively translate policies to programs for communities ➤ Highlighting different multi-stakeholder initiatives that are improving access to services such as testing and care for people living with viral hepatitis <p>Chairs:</p> <ul style="list-style-type: none"> ● Rachel Halford, Hepatitis C Trust, WHA EURO board member <p>Welcome and opening remarks</p> <p>Community values and preferences for hepatitis C testing and treatment <i>Rosemary Delabre, Coalition Plus, France</i></p> <p>Cross-sector partnerships to eliminate hepatitis B inequities in the US <i>Catherine Freeland, Hepatitis B Foundation, USA</i></p> <p>Community-led HCV And HBV care model, including same-day HCV “test and treat” <i>Nalinkanta Rajkumar, Community Network for Empowerment, India</i></p> <p>Nurse-led hepatitis C testing and treatment in a rural setting in Battambang province, Cambodia <i>Dr Daniel O’Keefe</i></p> <p>Hepatitis C micro-elimination among underserved communities of Islamabad-Federal capital of Pakistan <i>Dr Huma Qureshi, Integral Global, Pakistan</i></p>

17.13-17.20	Community leadership mobilising Australia to achieve its national hepatitis C treatment target <i>Amanda Bode, Hepatitis Australia, Australia</i>
17.20-17.30	Q&A and closing remarks
	<p>Leave no one behind</p> <ul style="list-style-type: none"> ➤ Exploring the issues which lead to health inequality in term of viral hepatitis ➤ Discussing best practice on how to meet the needs of highly affected groups not well served by health systems ➤ Learning about the community perspectives regarding the issue <p>Chair</p> <ul style="list-style-type: none"> ● Niklas Luhmann, WHO, Switzerland
16.30-16.40	Welcome and opening remarks
16.40-16.47	Seroprevalence of hepatitis B in pregnant Syrian refugees <i>Dr Sukran Kose, Izmir University of Health Sciences Tepecik Training and Research Hospital, Turkey (TBC)</i>
16.47-16.54	Hepatitis A, B and C seroprevalence in vulnerable Quilombola population from northeast Brazil <i>Livia Melo Villar, Fiocruz, Brazil</i>
16.54-17.01	Epidemiological trends of hepatitis B and C in Lahore Pakistani for MSM population <i>Syed Raza Haider Tirmizi, Dostana Male Health Society, Pakistan</i>
17.01-17.08	Pilot project - HDV: An awareness campaign with the Mongolian community in Germany <i>Achim Kautz, Kautz5 Gug, Germany</i>
17.08-17.30	Q&A and closing remarks
17.30-18.30	Symposium

18.30-19.30	WHA 15th Anniversary Party

WEDNESDAY 8 JUNE, 2022

Time	Outline
12.00-13.00	Symposium - Gilead
13.00-14.30	<p>A whole system approach to hepatitis elimination</p> <ul style="list-style-type: none"> ➤ Accelerating progress through collaboration, integration and cooperation with related conditions and across health systems in the pursuit of achieving health for all <p>Chair: Cary James, World Hepatitis Alliance, UK</p> <p>Panellists: Luís Mendão, GAT Dr Carla Vizzotti, Minister of Health, Argentina (TBC) Dr Cary Adams, UICC Dorothy Mbori-Ngacha, UNICEF Oanh Khat, Center for Supporting Community Development Initiatives</p>
14.30-15.30	<p>Hepatitis and liver cancer: Gaps and opportunities</p> <ul style="list-style-type: none"> ➤ Leveraging links with liver cancer, including cancer prevention efforts to help drive hepatitis elimination

	<p>➤ Address gaps in global liver cancer surveillance in people living with viral hepatitis and role of innovative diagnostics and treatments</p> <p>Chairs:</p> <ul style="list-style-type: none"> • Maria Buti – EASL, Spain • Gamal Shiha, Egyptian Liver Research Institute and Hospital (ELRIAH), WHA EMRO Board Member
14.30-14.35	Welcome and opening remarks
14.35-14.42	<p>Personal story <i>Ibrahima Gueye, Senegal</i></p>
14.42-14.49	<p>Hepatitis and liver cancer control: The urgency of implementing what we know <i>Prof Dr Lewis Roberts, Mayo Clinic, USA</i></p>
14.49-14.56	<p>Viral hepatitis and liver cancer awareness month <i>Luciana Holtz, Oncoguia Cancer organisation in Brazil</i></p>
14.56-15.03	<p>Liver cancer, viral hepatitis and other major risk factors: A review of the Western Pacific region <i>Dr Eleonora Feletto, The University of Sydney And Cancer Council NSW, Australia</i></p>
15.03-15.10	<p>How a white paper on liver cancer can contribute to hepatitis elimination <i>Marko Korenjak, ELPA, Slovenia (TBC)</i></p>
15.10-15.17	<p>Changing viral etiology of hepatocellular carcinoma in Taiwan <i>Wan-Long Chuang, Taiwan Liver Research, Taiwan</i></p>
15.17-15.30	Q&A and closing remarks
Fighting stigma and discrimination to achieve social and legal justice	

	<ul style="list-style-type: none"> ➤ The impact of stigma and discrimination globally on people living with hepatitis (PLVH) is often overlooked, yet it is a significant barrier to PLVH accessing care. It also has serious implications for many dimensions of their life, including mental health. ➤ How do we capture the experiences of PLVH in regards to stigma and discrimination? ➤ How do we combat stigma and discrimination in order to achieve social and legal justice? <p>Chairs:</p> <ul style="list-style-type: none"> • Professor Carla Treloar University of New South Wales, Australia • Chris Munoz, Yellow Warriors Society, Philippines
14.30-14.35	Welcome and opening remarks
14.35-14.42	WHA hepatitis B stigma report and hepatitis C stigma survey findings <i>Jessica Hicks, WHA, UK</i>
14.42-14.49	HIV stigma index <i>Caroline Thomas</i>
14.49-14.56	The global impact of discrimination on people with hepatitis B <i>Catherine Freeland, Hep B Foundation, USA</i>
14.56-15.03	How stigma and discrimination affecting the elimination of HBV? Findings in 5 Asian countries <i>Dee Lee, Inno Community Development Organisation, China</i>
15.03-15.10	Stigma associated diagnosis of hepatitis B and depression among patients with chronic hepatitis B <i>Professor Hee-Soon Juon, Thomas Jefferson University, USA</i>
15.10-15.17	A mixed method study to assess the social challenges experienced by hepatitis B patients (India) <i>Meenakshi Tomar, Institute of Liver and Biliary Sciences, India</i>
15.17-15.30	Q&A and closing remarks

	<p>Hepatitis integration with health systems: Opportunities with Universal Health Coverage, Primary Health Care and HIV Services</p> <p>Co-Chairs:</p> <ul style="list-style-type: none"> • Dr Po-Lin Chan, WHO, India • Dr Patricia Vélez Möller, Guatemalan Association of the Liver, WHA PAHO Board Member
14.30-14.37	Welcome and opening remarks
14.37-14.44	<p>CSEM UHC2030 - UHC tool kit <i>Eliana Monteforte, Global Health Council</i></p>
14.44-14.51	<p>Community-based and HIV integrated screening for hepatitis B and C among key populations in Vietnam <i>Dr Vu Ngoc Bao, Path, Vietnam</i></p>
14.51-14.58	<p>Achieving global hepatitis elimination: A case study of Elohim Foundation/ FHI360 Epic Project in Nigeria <i>Dr Julius Uchechukwu Ibecheole, Elohim Foundation, Nigeria</i></p>
14.58-15.05	<p>The Failure of The Colombian Insurance-Based Health System for Hepatitis C Elimination in Colombia (7 mins) <i>Dr Francisco Augusto Rossi, IFARMA Foundation, Colombia</i></p>
15.05-15.30	Q&A and closing remarks
	<p>Lightning talks: Oral abstracts of distinction - <i>Prevention and vaccination</i></p> <p>Chair: Dr Ahmed Elsharkawy, University of Birmingham, UK</p>
15.30-15.35	<p>Customized active engagement can increase hepatitis B vaccine adherence in remote tribal communities <i>Dr Partha Sarathi Mukherjee, Liver Foundation, West Bengal, India</i></p>
15.35-15.40	<p>Advancing health equity in the US by increasing adult hepatitis B vaccination <i>Michaela Jackson, Hepatitis B Foundation, USA</i></p>

15.40-15.45	<p>A Systematic Review of Effectiveness, Immunogenicity and Impact of Paediatric Hepatitis A Vaccines (5 mins) <i>Dr Nick Walsh, Monash University, Australia</i></p>
15.45-15.50	<p>High Prevalence of Hepatitis A and E Viruses in Environmental and Clinical Samples from West Argentina (5 mins) <i>Livia Melo Villar, Fundação Oswaldo Cruz, Brazil</i></p>
15.50-16.00	<p>Q&A and closing remarks</p>
16.00-17.00	<p>Hepatitis and the Sustainable Development Goals</p> <ul style="list-style-type: none"> ➤ Beyond SDG 3.3, what other SDGs can contribute and play a role in hepatitis elimination? <p>Chair:</p> <ul style="list-style-type: none"> ● Cary James, World Hepatitis Alliance, UK <p>Panellists:</p> <p>Julia Tainijoki Seyer, World Medical Association Dr Justin Koonin, co-chair UHC2030, Australia Amina Mohammed, UN (TBC) Dr José M. Zuniga, IAPAC and Fast-Track Cities Institute Dr Mandeep Dhaliwal, UNDP</p>
	<p>Bridging gaps in hepatitis B care and treatment: bringing science and affected communities together</p> <ul style="list-style-type: none"> ➤ Recognize gaps in hepatitis B care and treatment in lower, middle and high income countries ➤ Hear patient experience in accessing HBV care and treatment around the world ➤ Explore how affected communities can intersect with science to improve care with a lookback on the HIV experience ➤ Discuss opportunities for guideline adaptability in various settings, patient preferences and values, and the role of simplified and decentralized care to bridge current gaps <p>Chairs:</p>

<p>17.00-17.03</p> <p>17.03-17.10</p> <p>17.10-17.17</p> <p>17.17-17.24</p> <p>17.24-17.31</p> <p>17.31-17.41</p> <p>17.41-18.00</p>	<ul style="list-style-type: none"> • Dr Su Wang, Past President, World Hepatitis Alliance and Center for Asian Health and Viral Hepatitis Programs at Cooperman Barnabas Medical Center, USA • Philippa Easterbrook, WHO, Switzerland <p>Welcome and opening remarks</p> <p>Low income- Gaps in Hepatitis B care and treatment in Ethiopia and other countries <i>Dr Hailemichael Desalegn Mekonnen, St. Paul's Hospital Millennium Medical College, Ethiopia</i></p> <p>Middle income- Bridging gaps in hepatitis B care and treatment in China <i>Dr Fuqiang Cui, Peking University, China CDC, WHO, China</i></p> <p>High income- Hepatitis B care and treatment in the US <i>Dr Norah Terrault, AASLD, University of Southern California College, USA</i></p> <p>Perspective of people living with hepatitis B on access to care and treatment <i>Danjuma Adda, WHA and Center for Initiative and Development (CFID) and Chagro-Care Trust (CCT), Nigeria</i></p> <p>TAG: Lookback at HIV treatment evolution and the involvement of people living with HIV <i>Mark Harrington, TAG, USA</i></p> <p>Q&A and closing remarks</p>
	<p>Youth Can't Wait</p> <ul style="list-style-type: none"> ➤ Understanding the experience and needs of young people living with viral hepatitis including the medical and psychological impacts. ➤ Defining ways to empower young PLVH to live full and healthy lives and to become advocates for change. ➤ Bringing the energy and activism of youth into the VH elimination movement. <p>Chairs:</p> <ul style="list-style-type: none"> • Dr Tasnia Noor, Bangladesh Medical Students' Society, Bangladesh • Matthew Bonn, Canadian Association of People Who Use Drugs, Canada

17.00-17.05	<p>Welcome and my personal story Matthew Bonn, Canadian Association of People Who Use Drugs, Canada</p>
17.05-17.10	<p>My personal story David Urick, USA</p>
17.10-17.17	<p>Perceived supportive care needs of adolescents with chronic hepatitis B in Ghana <i>Charles Ampong Adjei, University of Ghana, Ghana</i></p>
17.17-17.24	<p>The innovative use of TikTok to increase community engagement on hepatitis awareness <i>Annika Martin, Hawaii Health and Harm Reduction Center, USA</i></p>
17.24-17.31	<p>An initiative to incorporate children, adolescents and pregnant people in elimination efforts <i>Ronni Marks, The Hepatitis C Mentor and Support Group, USA</i></p>
17.31-17.36	<p>The importance of a youth centered movement response in the HIV response and lessons for hepatitis <i>Wole Ameyan, WHO, Switzerland</i></p>
17.36-17.41	<p>How providers and others can support a hepatitis youth movement <i>Professor Manal El Sayed, Ain Shams University, Egypt</i></p>
17.41-18.00	<p>Q&A and closing remarks</p>
	<p>Reaching communities that need it most</p> <ul style="list-style-type: none"> ➤ Learning about the public health importance of key populations and viral hepatitis elimination ➤ Showcasing best practices in delivering services to key populations ➤ Learning about the community perspectives regarding the issue <p>Chair:</p> <ul style="list-style-type: none"> ● Andrew Scheibe, TB HIV Care, South Africa

17.00-17.07	Welcome and opening remarks
17.07-17.14	My personal story TBC
17.14-17.21	Going beyond low-hanging fruit: Key population-specific strategies to tackle hepatitis C in Malaysia <i>Dr Muhammad Radzi Abu Hassan, Hospital Sultanah Bahiyah, Malaysia</i>
17.21-17.28	Reach_U: Peer and nursing-led point-of-care HCV testing and treatment combined with outreach work <i>Cristiana Merendeiro, Crescer - Associação De Intervenção Comunitária, Portugal</i>
17.28-17.35	HCV micro-elimination efforts in the prisons of Punjab and Haryana, India <i>Dr Kanudeep Kaur, Find India, India</i>
17.35-17.42	Hepatitis C test and treat roadshow – reaching homeless communities <i>Philippe Bonnet and Danny Morris, Hepatitis C Trust, UK</i>
17.42-17.49	C-Free: Community-based testing and treatment of HCV, HBV & HIV in people who use drugs in Thailand <i>Tanyaporn Wansom</i>
17.49-18.00	Q&A and closing remarks
18.00-19.00	Symposium Urban HCV Elimination: Lessons from Fast-Track Cities Sponsor: IAPAC Moderator: José M. Zuniga, IAPAC and Fast-Track Cities Institute

	<p>Panelists:</p> <p>Leveraging Urban HCV Elimination for National Impact Dr Meg Doherty, WHO, Switzerland</p> <p>Case Study: Advancing HCV Elimination Goals in Spanish Cities (TBC)</p> <p>Case Study: Urbanizing Rwanda’s National HCV Elimination Plan (TBC)</p> <p>Closing Remarks</p>
--	--

THURSDAY 9 JUNE, 2022

Time	Outline
08.00-08.05	<p>Viral hepatitis response in the Western Pacific region</p> <p>Chairs:</p> <ul style="list-style-type: none"> • Dr Sahar Bajis, WHO, Manila • Professor Benjamin Cowie, The Peter Doherty Institute for Infection and Immunity, Australia <p>Welcome and opening remarks</p>
08.05-08.15	<p>Learnings from a national implementation <i>Dr Jacqui Richmond, Burnet Institute, Australia</i></p>
08.15-08.30	<p>Response to the high prevalence of viral hepatitis in Kiribati <i>Dr Thomas Tibwere Russell, Tungaru Central Hospital, Kiribati</i></p>
08.35-08.45	<p>Bridging the gap</p>

<p>08.45-09.00</p> <p>09.00-09.15</p> <p>09.15-09.30</p> <p>09.30-10.00</p>	<p><i>Patrick Bantayan Saburit, Yellow Warriors Society of the Philippines, Philippines</i></p> <p>Progress of triple elimination of mother to child transmission of HIV, syphilis and Hepatitis B, in China <i>Dr Wang Ai-Ling, National Center for Women and Children's Health, China CDC</i></p> <p>Malaysia's Journey to HCV elimination: From compulsory licensing to treatment decentralization <i>Dr Muhammad Radzi bin Abu Hassan, Ministry of Health Malaysia</i></p> <p>Successes and challenges with viral hepatitis elimination in Mongolia <i>Dr S Amarzaya, Ministry of Health, Mongolia</i></p> <p>Q&A Panel <i>Dr Wang Ai-Ling (China)</i> <i>Dr Muhammad Radzi bin Abu Hassan (Malaysia)</i> <i>Dr S Amarzaya (Mongolia)</i></p> <p>Closing remarks</p>
<p>08.00-08.05</p> <p>08.05-08.15</p> <p>08.15-08.55</p>	<p>Viral hepatitis response in the African region: Promoting hepatitis B PMTCT in Africa, experience from the first implementers in Africa</p> <p>Chairs</p> <ul style="list-style-type: none"> • Casimir Manzengo, Chair • Danjuma Adda, Co-Chair <p>Opening remarks <i>UCN Director</i></p> <p>Where are we in Africa on the viral hepatitis B PMTCT? <i>Casimir Manzengo, WHO / AFRO</i></p> <p>Partners panel:</p>

	<p>Viral hepatitis response in the Eastern Mediterranean region</p> <p>Objectives</p> <ul style="list-style-type: none"> ➤ Review regional progress and challenges including country examples. ➤ Advocate for scaling up Hep B birth dose coverage. <p>Chair:</p> <ul style="list-style-type: none"> • Joumana Hermez, WHO/EMRO
09:00-09.05	<p>Welcome and opening remarks</p>
09.05-09.20	<p>Regional progress of hepatitis elimination in the EMR - midterm review findings <i>Ahmed Sabry, WHO/EMRO</i></p>
09.20-09.40	<p>Sudan costed operational plan and prioritization: Opportunities and challenges of a low-income country <i>Dr Sara Abdallah</i></p>
09.40-09.50	<p>Morocco progress and updated country targets: Refocusing a national response based on epidemiology <i>Dr Ibtissam Khoudari</i></p>
09.50-10.05	<p>Public – private partnership for rapid scale-up of hepatitis testing and treatment <i>Dr Muhammad Ahmar Khan (TBC)</i></p>
10.05-10.20	<p>Q&A and discussion</p>
10.20-10.50	<p>Panel discussion - Hepatitis B elimination: A need for aligned approaches</p> <p>Moderator: Gamal Shiha, Egyptian Liver Research Institute and Hospital (ELRIAH), WHA EMRO Board Member</p>
10.50-11.15	<p><i>Dr Akram Shah, Pakistan (TBC)</i> <i>Dr Delwair Noorzai, Afghanistan</i></p>

	<p><i>Dr Jamila Taiseer Al Abri, Ministry of Health, Oman</i></p> <p>Q&A and closing remarks</p>
	<p>Viral hepatitis response in the European region</p>
09.30-09.35	<p>Welcome remarks</p> <ul style="list-style-type: none"> • Nicole Seguy, WHO/Europe, Denmark • Cary James, World Hepatitis Alliance, UK
09.35-09.40	<p>Meeting objectives and agenda Nicole Seguy, WHO/Europe</p> <p>Session 1: World Hepatitis Summit 2022 Abstracts Chairs:</p> <ul style="list-style-type: none"> • Cary James, World Hepatitis Alliance, UK • Marcelo Naveira, WHO/Europe, Denmark
09.40-09.50	<p>The reality of HCV care in Ireland in 2021: Understanding complex barriers to elimination <i>Nicola Perry and Marcus Keane, The Hepatitis C Partnership, Ireland</i></p>
09.50-10:00	<p>National program for prevention and control of chronic hepatitis B and hepatitis C in Serbia <i>Dr Nikola Mitrovic, Serbia (TBC)</i></p>
10.00-10.10	<p>“ACCESS4ALL”: a holistic intervention for HCV micro-elimination among people in Greek prisons <i>Giannis Petalidis, Hellenic Liver Patients Association "Prometheus", Greece</i></p>
10.10-10.25	<p>Q&A</p> <p>Session 2: Good practices and key actions towards elimination Chairs:</p> <ul style="list-style-type: none"> • Rachel Halford, Hepatitis C Trust, WHA EURO board member, UK

<p>10.25-10.40</p> <p>10.40-10.55</p> <p>10.55-11.10</p> <p>11.10-11.25</p> <p>11.25-11.30</p>	<ul style="list-style-type: none"> • Antons Mozalevskis, WHO, Switzerland <p>Strategic plan for tackling hepatitis C in the Spanish National Health System <i>Dr Julia del Amo, National Center for Epidemiology, Institute of Health Carlos III, Spain</i></p> <p>Uzbekistan Hepatitis Elimination Project (UHEP) <i>Dr Erkin Musabaev, Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, Uzbekistan</i></p> <p>HBV/HCV prevention, testing and linkage to care for PWID <i>Dr Maia Tskhomelidze, National Center for Disease Control and Public Health, Georgia</i></p> <p>Q&A</p> <p>Next steps and closing Nicole Seguy, WHO/Europe, Denmark</p>
<p>10.00-10.05</p> <p>10.05-10.10</p> <p>10.10-10.20</p>	<p>Viral hepatitis response in the South-East Asian region</p> <p>Chairs:</p> <ul style="list-style-type: none"> • Dr Olufunmilayo Lesi, WHO, Switzerland • Dr Bharat Bhushan Rewari, WHO, India <p>Welcome and opening remarks</p> <p>A brief overview of hepatitis situation and regional priorities (2022-2026) <i>Dr Suman Rijal, WHO (TBC)</i></p> <p>Experiences in testing for hepatitis B and providing Hepatitis B vaccination for adult key populations in Timor-Leste <i>Sr Bernardino, National Programme Manager, HIV and hepatitis, Timor Leste</i></p>

10.20-10.30	<p>Reaching out to grassroots through linkages with primary health care and simplified algorithms – the Delhi experience <i>Dr Ekta Gupta, Institute of Liver and Biliary Sciences, New Delhi, India</i></p>
10.30-10.40	<p>Adopting simplified treatment guidelines and capacity strengthening at grassroots – experiences from Myanmar <i>Dr Khin Sandar Aung, National programme Manager Hepatitis, Myanmar (TBC)</i></p>
10.40-10.50	<p>Towards an integrated DHIS2 based system for hepatitis B and C monitoring and reporting in Bhutan <i>Lekey Khandu, National HIV/STI/Hepatitis Control Program, Department of Public Health, Ministry of Health, Bhutan (TBC)</i></p>
10.50-11.00	<p>Preventing mother to child prevention transmission of hepatitis B – experience from Indonesia <i>Dr Fatchanuradiyah, SKM, Viral Hepatitis Programme, Ministry of Health, Jakarta, Indonesia (TBC)</i></p>
11.00-11.10	<p>Challenges on scaling up hepatitis B birth dose vaccination in SEARO <i>Dr Sigrun ROESEL, WHO</i></p>
11.10-11.20	<p>A regional capacity strengthening initiative on hepatitis through WHO SEARO partnership with Project ECHO <i>Dr Nabeel Mangadan-Konath, WHO</i></p>
11.20-12.00	<p>Panel discussion - role of communities and civil societies in accelerating the hepatitis agenda in the region Moderated by:</p> <ul style="list-style-type: none"> • Professor RP Shanmugam, Chennai Liver Foundation, WHA SEARO Board Member (India) (TBC) • Giten Khwairakpam, Treat Asia, Thailand (TBC) • Han Yung, DNDi
12.00-12.10	<p>Closing remarks <i>Dr Olufunmilayo Lesi, WHO, Switzerland</i> <i>Dr Bharat Bhushan Rewari, WHO, India</i></p>
13.30-15.00	<p>Acute viral hepatitis session</p>

	<p>Viral hepatitis response in the Pan American region</p>
15:30-15:40	<p>Welcome remarks</p> <ul style="list-style-type: none"> • Dr Patricia Vélez Möller, Guatemalan Association of the Liver, WHA PAHO Board Member • Dr Rubén Mayorga-Sagastume, WHO
15.40-15.50	<p>Overview of viral hepatitis in the region of the Americas and the role of civil society Dr Patricia Vélez Möller, Guatemalan Association of the Liver, WHA PAHO Board Member</p> <p>Session 1: National Programs Chairs:</p> <ul style="list-style-type: none"> • Dr John Ward, Coalition for Global Hepatitis Elimination, USA • Dr Leandro Sereno, PAHO/WHO, USA
15.50-16.02	<p>Micro elimination of hepatitis B in Peru <i>Dr Carlos Benites, Ministry of Health, Peru (TBC)</i></p>
16.02-16.14	<p>Guyana: Building the national viral hepatitis response and opportunities for integration <i>Dr Frank Anthony, Minister of Health of Guyana</i></p>
16.14-16.26	<p>Opportunities for subregional cooperation: Viral hepatitis elimination in the Andean Region <i>Andean Health Organism (ORAS)</i> <i>Dr Paolo Balladelli, PAHO/WHO Subregional Program for South America</i></p>
16.26-16.38	<p>Financing the national response to hepatitis C in Mexico <i>Dr Alethse de la Torre Rosas, CENSIDA, Secretary of Health, Mexico (TBC)</i></p>
16.38-16.50	<p>Development of the U.S. viral hepatitis national strategic plan and federal implementation plan 2021 <i>Dr Jessica Deerin, U.S. Department of Health and Human Services (TBC)</i></p>

16.50-17.20	<p>Q&A</p> <p>Session 2: Experiences from the Civil Society</p> <p>Chairs:</p> <ul style="list-style-type: none"> • Dr Sergio Sosa-Estani, DNDi • Dr Su Wang, World Hepatitis Alliance and Center for Asian Health and Viral Hepatitis Programs at Cooperman Barnabas Medical Center, USA
17.20-17.30	<p>The experience of Achcu civil organization in Uruguay <i>Victoria Izquierdo, Asociación Comunidad Hepatitis C, Uruguay</i></p>
17.30-17.40	<p>Building and advocating for a national law for viral hepatitis <i>Carolina Meijon, Fundación HCV Sin Fronteras, Argentina</i></p>
17.40-17.50	<p>ALEH: Project for micro elimination of hepatitis C in dialysis patients <i>Dr Marcelo Silva, Latin American Association for the Study of the Liver (ALEH)</i></p>
17.50-18.00	<p>Canada's progress toward viral hepatitis elimination 2021 report: Holding governments accountable <i>Jennifer Van-Gennip (TBC)</i></p>
18.00-18.30	<p>Q&A and closing remarks</p>

FRIDAY 10 JUNE, 2022

Time	Outline
	<p>Hepatitis B Functional cure</p> <p>Chairs:</p> <ul style="list-style-type: none"> • Dr Su Wang, Past president World Hepatitis Alliance, and Center for Asian Health and Viral Hepatitis Programs at Cooperman Barnabas • Professor Harry Janssen, Erasmus University, Rotterdam
11.00-11.10	<p>Welcome and opening remarks</p>
11.10-11.18	<p>101 of hepatitis B virology and immunology <i>Dr Thomas Tu, HepBCommunity.org, Australia</i></p>
11.18-11.26	<p>What are our approaches to hepatitis B cure and how far are we? <i>Dr Kosh Agarwal, Kings College Hospital, UK</i></p>
11.26-11.34	<p>Engaging the affected community: What people living with hepatitis B really want <i>Chari Cohen, Hepatitis B Foundation, USA</i></p>
11.34-11.40	<p>The access question: Lesson's learned from hepatitis C and other drugs on global access <i>Jessica Burry, Médecins Sans Frontières, Switzerland</i></p>
11.40-11.48	<p>The regulatory riddle and research partnerships <i>Veronica Miller, Forum for Collaborative Research, USA</i></p>
11.48-11.58	<p>Q&A</p>
11.58-12.05	<p>Closing remarks <i>Professor John Tavis, Saint Louis University, USA</i></p>

12.15-12.45	Symposium - AbbVie
13.00-14.30	<p>Financing for hepatitis</p> <ul style="list-style-type: none"> ➤ Country led discussion on different innovative and sustainable financing models and the role of commodities in the financing discussion ➤ Exploration of what has proven to be feasible, or not feasible, when financing viral hepatitis programmes <p>Chairs:</p> <ul style="list-style-type: none"> ● Finn Jarle Rode, EndHep 2030, Switzerland ● Jessica Hicks, World Hepatitis Alliance, UK <p>Panellists:</p> <p><i>Homie Razavi, Center for Disease Analysis Foundation, USA</i> TBC, DNDi State Governor of Nasawara State, Nigeria State Governor of Taraba State, Nigeria</p>
14.30-14.35 14.35-14.43	<p>The role of good data, surveillance, monitoring and evaluation in elimination</p> <ul style="list-style-type: none"> ➤ The importance of data, gaps in surveillance and representation, and how a multi-stakeholder effort can lead to better data collection, interpretation and dissemination for a more impactful response ➤ Understanding data tools/approaches that VH programs have effectively utilised to strengthen the cascade of care and improve decision-making <p>Chairs:</p> <ul style="list-style-type: none"> ● Dr Carolyn Wester, CDC, USA ● Professor Jeff Lazarus, Barcelona Institute for Global Health (ISGLOBAL), Spain <p>Welcome and opening remarks</p> <p>Surveillance for hepatitis - making the hepatitis country data collection system work better <i>Daniel Low Beer, WHO, Switzerland</i></p>

14.43-14.51	Data for advocacy – prioritisation and innovations to improve information for action <i>Erika Duffell, ECDC, Sweden</i>
14.51-14.59	Closing the loop...utilising data tools to effectively reduce loss to follow up <i>Alida Ngwije, CHAI Rwanda, Rwanda</i>
14.59-15.07	Uptake of Hepatitis B and C antiviral treatment before and after national policy changes in China <i>Professor Jing Sun, Peking University</i>
15.07-15.30	Q&A and closing remarks
	<p>Covid19: Impact and opportunities</p> <ul style="list-style-type: none"> ➤ Understanding how to maximise opportunities the Covid-19 pandemic has created ➤ What barriers are there and how do we overcome them? <p>Co-Chairs:</p> <ul style="list-style-type: none"> • John Ward, Global Coalition for Hepatitis Elimination, USA • Mohammed Abdulaziz, Africa CDC, Ethiopia
14.30-14.35	Welcome and opening remarks
	Country experience round table
14.35-14.42	Combined covid-19 vaccination and HCV and HIV screening for high-risk populations in Madrid, Spain <i>Professor Jeff Lazarus, Barcelona Institute for Global Health (ISGLOBAL), Spain</i>
14.42-14.49	Scaling-up HBV testing and treatment during covid-19: Experience of pilot in central Philippines <i>Eugene Matildo Arbis, WHO Philippines (TBC)</i>
14.49-14.56	Enhancing inter-island hepatitis C care networks in Hawaii with Project Echo during covid-19 <i>Dr Dan Saltman, Hawaii Learning Groups, USA</i>

14.56-15.03	<p>Covid-19 impact and response on hepatitis B virus and hepatitis C virus prevention and care in Japan <i>Md Razeen Ashraf Hussain, Hiroshima University, Japan</i></p>
15.03-15.10	<p>Complementarity between community HCV care and health care services in the time of covid-19 <i>Maria Donatelli Klinger, Coalition Plus, France</i></p>
15.10-15.30	<p>Q&A and closing remarks</p>
	<p>Innovations in technology and service delivery</p> <p>➤ Looking at new technologies that are currently available and how they can help us better reach people living with viral hepatitis key populations or the general population; explore mechanisms of dismantling barriers to accessing testing and care, including innovations outside the hep space</p> <p>Chair:</p> <ul style="list-style-type: none"> • Margaret Hellard, Burnet Institute, Australia
14.30-14.35	<p>Welcome</p>
14.35-14.50	<p>Hepatitis C self-testing</p> <p>Introduction: Sonjelle Shilton, FIND, Switzerland HCVST impact study in Georgia among key pops: <i>Dr Ketevan Stvilia, National Center for Disease Control (NCDC), Georgia (TBC)</i> HCV self-testing experiences from Pakistan: <i>Dr Aliya Hasnain, Aga Khan University, Pakistan</i></p>
14.50-14.57	<p>HBV and HCV Prevalence and acceptability of the plasma separation card for viral hepatitis <i>Camila Picchio, Barcelona Institute for Global Health (ISGlobal), Spain</i></p>
14.57-15.04	<p>Quick Start Hepatitis C Treatment <i>Sunil Solomon, Johns Hopkins Medicine, USA</i></p>

15.04-15.11	The Effectiveness of Low Dead Space Syringes for Reducing the Risk of Hepatitis C Virus Acquisition (7 mins) <i>Professor Peter Vickerman, University of Bristol, UK</i>
15.11-15.30	Q&A and closing remarks
	Lightning talks: highlighting abstracts of distinction - <i>Delivering Innovations to People Living with Viral Hepatitis</i> Chair: TBC
15.30-15.35	Welcome
15.35-15.40	Interventions to improve HCV care for people who inject drugs: A systematic review and meta-analysis <i>Evan Cunningham, Australia</i>
15.40-15.45	HepBcommunity.Org: A global online forum dedicated to supporting people with hepatitis B <i>Dr Thomas Tu, HepBCommunity.org, Australia</i>
15.45-15.50	Kindness begets kindness: Pay-it-forward approach to increase HBV and HCV testing uptake among MSM <i>Ye Zhang, Australia</i>
15.50-15.55	HBV commodities pricing and access strategies <i>Capucine Pénicaud, ICE-HBV, Australia</i>
15.55-16.00	Equitable access to HCV comprehensive package of services for PWID In Ukraine – Is this a reality? <i>Zahedul Islam, ICF "Alliance for Public Health", Ukraine (TBC)</i>
16.00-16.30	Q&A and closing remarks
16.30-17.30	Hep Can't Wait and closing remarks ➤ A session reflecting on the human impact on hepatitis, why hepatitis matters and why Hep Can't Wait

Chair:

Danjuma Adda, President the World Hepatitis Alliance and Executive Director, Center for Initiative and Development (CFID) and Chagro-Care Trust (CCT)

Hep Can't Wait

Reflections from people living with viral hepatitis and the community on WHS 2022 and why Hep Can't Wait

Reading of WHS 2022 Statement

Closing

Cary James, World Hepatitis Alliance, UK
Dr Meg Doherty, WHO, Switzerland

*All session are open to all participants
All times are CET*

There will be Spanish and French interpretation available